CORTEXA
← Browse
openalexFrontiers in Oncology2026-07-24Cited by 0

Down-regulation of THBS2 inhibits the malignant progression of Burkitt lymphoma by blocking the PI3K/AKT/c-MYC pathway

Yan Xu, Shengquan Liu, Shaoxiong Wang, Y Huang

Background Thrombospondin 2 (THBS2) is overexpressed in various solid tumors and is a prognostic gene of Burkitt lymphoma (BL), but its role and molecular mechanism in BL still need to be explored. Methods Western blot (WB) detected the protein expression of THBS2 in BL cells. si-THBS2 was transfected into CA46 and RAJI cells to detect cell malignant phenotype and cell cycle changes. WB detected the protein expression of epithelial-mesenchymal transition (EMT), apoptosis, cell cycle and the PI3K/AKT/c-MYC pathway proteins. ChIP-qPCR detected the binding ability of MYC to target gene promoters, and Co-IP detected the level of MYC/MAX dimerization. Tumor stem cell sphere formation assays evaluated cell stemness changes. The subcutaneous xenograft model of RAJI cells was developed to observe the effect of THBS2 knockdown on tumor growth. Results THBS2 protein was markedly up-regulated in BL cells. Knockdown of THBS2 could inhibit the growth and EMT process, inhibit the protein levels of cyclins (CDK2, CDK4, CDK6 and CyclinD1), inhibit the sphere formation ability of stem cells and down-regulate SOX2 and OCT4 expressions. THBS2 knockdown inhibited the PI3K/AKT pathway phosphorylation, declined c-MYC expressions, weakened the MYC/MAX dimerization and the binding ability of MYC to target gene promoters. In addition, THBS2 knockdown also significantly inhibited the growth of subcutaneous xenografts of RAJI cells, reduced the positive rates of Ki67 and PCNA, declined the protein levels of cyclins, and inhibited the PI3K/AKT/c-MYC pathway. Overexpression of c-MYC or 740Y-P treatment partially reversed the tumor malignant phenotype inhibition caused by THBS2 knockdown and partially restored cyclin levels. Conclusion Knockdown of THBS2 inhibited the malignant phenotype, EMT and stem cell-like characteristics via inhibiting the PI3K/AKT/c-MYC signaling axis, and blocked the cell cycle.

View free PDFSource page

Related papers

openalexFrontiers in Oncology2026-07-24

Enzalutamide promotes an early plasticity-associated transcriptional state without terminal neuroendocrine differentiation in prostate cancer cells

R K Watanabe, Mami Chosei, Haruna Arai, Noriyoshi Miura, Tadahiko Kikugawa, Takashi Saika

Introduction Neuroendocrine prostate cancer (NEPC) is an aggressive treatment-associated lineage state emerging with potent androgen receptor (AR) pathway inhibition. Although treatment-emergent NEPC is increasingly recognized, the transcriptional consequences of sustained AR sup…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Phosphorylation of tumour suppressor Amotl2 by IKBKE kinase promotes YAP1 signalling, enhancing glioblastoma growth

Gaochao Guo, Yan Sun, Rujun Hong, Yalin Lu, Xingjie Chen, Liming Zhao, et al.

Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE), a member of the serine/threonine kinase family, is an important oncogene in glioblastoma. IKBKE is involved in the progression of multiple tumours in glioblastoma (GBM), including tumour invasion, migration, and…

View free PDFSource page
crossrefFrontiers in Oncology2026-07-09

Plasticizers and prostate cancer: unraveling the link through network toxicology and machine learning

Yiting Jiang, Jiang Shi, Shiwang Yuan, Jun Qiao, Yuan Tian, Peng Chen, et al.

Background Plasticizers, as widespread environmental endocrine disruptors, are increasingly linked to an elevated risk of prostate cancer (PCa). However, the specific molecular mechanisms by which they drive PCa initiation and progression remain incompletely elucidated. Addressin…

View free PDFSource page
openalexFrontiers in Oncology2026-07-23

Editorial: Liquid biopsy in non-small cell lung cancer for diagnosis, treatment selection and monitoring

A. Strati, Benoît Roch, Ammar Sukari

Lung cancer is the third most common malignancy in the United States and remains the leading cause of cancer-related mortality worldwide. Despite ongoing advances in diagnosis and therapy, survival rates for patients with lung cancer remain unsatisfactory (1). In recent years, in…

View free PDFSource page
openalexFrontiers in Oncology2026-07-23

Tumor progression is effectively suppressed by miR-195 through direct targeting of YAP1

Wang Xiao-wei, Jin‐Chao Song, Ming-Ming Tang, Yi-Yu He, Zhigang Cai

Background Yes-associated protein 1 (YAP1) dysregulation is frequently observed in various human cancers. This study aimed to identify microRNAs (miRNAs) capable of suppressing YAP1 expression and to elucidate their functional roles in tumor progression. Methods We screened five…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Editorial: Innovative diagnostic and therapeutic strategies for neuroendocrine tumors: a multidisciplinary approach

Patricia Borges de Souza, Matteo Zurlo, Sara BRAVACCINI, Martina Rosticci, Massimiliano Mazza, Maria Chiara Zatelli

In this context, this Research Topic was conceived to highlight innovative diagnostic and therapeutic strategies to advance precision medicine in NENs. Although the contributions address diverse clinical and translational questions, they converge on a common theme: improving pati…

View free PDFSource page